They have one product, but their share structure is completely different. 75 million shares outstanding with 51 million in the float. With 435 million on that share structure they have an EPS around 9. Man of man, that that comes out to a multiple of around 14. Our structure is a lot different, but it shows how a company can explode if the products are suitable for a hungry market. LYMPRO could bring in that type of revenue just by itself.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links